Table 1.
Baseline demographic and clinical characteristics (n = 55)
| n (%) | |
|---|---|
| Sex | |
| Female | 28 (50.9) |
| Male | 27 (49.1) |
| Age at enrollment (years) | |
| Median [IQ-IIIQ] | 64 [55-73] |
| Min-max | 35-84 |
| ECOG PS | |
| 0 | 47 (85.5) |
| 1 | 8 (14.6) |
| DRE result | |
| Palpable | 33 (73.3) |
| Not palpable | 12 (26.7) |
| Not assessed | 10 |
| MRF status | |
| Negative | 23 (53.5) |
| Positive | 20 (46.5) |
| Missing | 12 |
| LPLN | |
| Negative | 30 (61.2) |
| Positive | 19 (38.8) |
| Missing | 6 |
| Distance to anal verge (mm) | |
| Median [IQ-IIIQ] | 50 [30-80] |
| Min-max | 0-160 |
| Missing | 2 |
| MRI cT | |
| T2 | 3 (5.6) |
| T3 | 42 (77.8) |
| T3a | 4 |
| T3b | 15 |
| T3c | 4 |
| T3d | 6 |
| Not available | 13 |
| T4 | 9 (16.7) |
| Missing | 1 |
| MRI cN | |
| N+ | 43 (79.6) |
| N0 | 11 (20.4) |
| Missing | 1 |
| Tumor dimension (mm) | |
| Median [IQ-IIIQ] | 50 [35-60] |
| Min-max | 7-100 |
| EMVI | |
| Positive | 6 (17.7) |
| Negative | 28 (82.4) |
| Not assessed | 21 |
| CEA (μg/l) | |
| Median [IQ-IIIQ] | 3 [1.9-5.6] |
| Min-max | 0.7-42 |
Percentages may not equal 100 due to rounding.
CEA, carcinoembryonic antigen; cN, clinical node; cT, clinical tumor; DRE, digital rectal exploration; ECOG PS, Eastern Cooperative Oncology Group performance status; EMVI, extramural vascular invasion; IQ, first quartile; IIIQ, third quartile; LPLN, lateral pelvic lymph nodes; MRF, mesorectal fascia; MRI, magnetic resonance imaging.